The director of the USC Michelson Center for Convergent Bioscience and the MESH Academy becomes the university’s second faculty member in the prestigious society. (April 18, 2019)

Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions. (January 23, 2019)

On NPR’s Joe’s Big Idea, Andrea Armani and Samantha McBirney explain the inspiration behind their work on malaria and their progress toward an inexpensive and effective early-detection device. (January 17, 2019)

USC News reports that Ellis Meng is one of two USC faculty members elected to the elite organization, which works to increase the visibility of academic technology and innovation. (December 11, 2018)

Scientists at the USC Michelson Center for Convergent Bioscience and Stanford University have taken the first steps toward making a safer drug for reducing maternal mortality. (December 3, 2018)

After seeing how his mother dealt with the disease, Peter Kuhn tackles the toughest questions about cancer. Kuhn is a cancer researcher at the USC Michelson Center for Convergent Bioscience. He studies how cancer invades the human body.

A trio of USC Viterbi researchers have unlocked secrets about an engineered protein receptor, known as CAR, that makes cancer-fighting T cells more effective. Assistant Professor Stacey Finley, Professor Pin Wang and Assistant Professor Nick Graham have just published a paper that sheds light on how this new treatment works.

USC Viterbi Magazine reports that USC’s “largest, most ambitious building is bringing together real life dynamic duos.” The building has brought together engineers, scientists and doctors to solve the biggest health issues of our time. (Fall 2018)

USC Viterbi reported that Eun Ji Chung has received the NIH New Innovator Award. With over $2.4 million in funding from this NIH grant, Chung will develop a new approach to autosomal dominant polycystic kidney disease (ADPKD). (October 2, 2018)

USC Viterbi reports that researchers from the USC Viterbi School of Engineering and the Keck School of Medicine at USC have engineered peptide nanoparticles that outsmart the biological system and target kidney cells, an innovation that may prove critical to addressing chronic kidney disease. (August 22, 2018)